Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.

Igawa Y, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):177-83. doi: 10.1007/s00210-012-0824-1. Epub 2012 Dec 21.

PMID:
23263450
2.

The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.

Svalø J, Nordling J, Bouchelouche K, Andersson KE, Korstanje C, Bouchelouche P.

Eur J Pharmacol. 2013 Jan 15;699(1-3):101-5. doi: 10.1016/j.ejphar.2012.11.060. Epub 2012 Dec 12.

PMID:
23246623
3.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
4.

In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats.

Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):247-53. doi: 10.1007/s00210-012-0821-4. Epub 2012 Dec 14.

PMID:
23239087
5.

Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats.

Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Kaku S.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Jan;386(1):71-8. doi: 10.1007/s00210-012-0814-3. Epub 2012 Dec 9.

PMID:
23224420
6.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.

Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048. Epub 2012 Nov 6.

PMID:
23195283
7.

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.

Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6.

PMID:
23182126
8.

Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ.

Clin Pharmacol Ther. 2012 Dec;92(6):696-706. doi: 10.1038/clpt.2012.181. Epub 2012 Nov 14.

PMID:
23149929
9.

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP; American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction.

J Urol. 2012 Dec;188(6 Suppl):2455-63. doi: 10.1016/j.juro.2012.09.079. Epub 2012 Oct 24.

PMID:
23098785
10.

Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S.

J Urol. 2013 Apr;189(4):1388-95. doi: 10.1016/j.juro.2012.10.017. Epub 2012 Oct 16.

PMID:
23079373
11.

Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.

Hood B, Andersson KE.

Int J Urol. 2013 Jan;20(1):21-7. doi: 10.1111/j.1442-2042.2012.03196.x. Epub 2012 Oct 17. Review.

12.

Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.

Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.

PMID:
23063375
13.

Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats.

Takahashi R, Yunoki T, Naito S, Yoshimura N.

J Urol. 2012 Nov;188(5):1993-9. doi: 10.1016/j.juro.2012.07.001. Epub 2012 Sep 20.

PMID:
22999538
14.

EAU guidelines on assessment and nonsurgical management of urinary incontinence.

Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, Neisius A, de Ridder DJ, Tubaro A, Turner WH, Pickard RS; European Association of Urology.

Eur Urol. 2012 Dec;62(6):1130-42. doi: 10.1016/j.eururo.2012.08.047. Epub 2012 Aug 31. Erratum in: Eur Urol. 2013 Jul;64(1):e20.

PMID:
22985745
15.

Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Aizawa N, Homma Y, Igawa Y.

Eur Urol. 2012 Dec;62(6):1165-73. doi: 10.1016/j.eururo.2012.08.056. Epub 2012 Sep 5.

PMID:
22981677
16.

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.

Eltink C, Lee J, Schaddelee M, Zhang W, Kerbusch V, Meijer J, van Marle S, Grunenberg N, Kowalski D, Drogendijk T, Moy S, Iitsuka H, van Gelderen M, Matsushima H, Sawamoto T.

Int J Clin Pharmacol Ther. 2012 Nov;50(11):838-50. doi: 10.5414/CP201782.

PMID:
22943933
17.

In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.

Takusagawa S, Miyashita A, Iwatsubo T, Usui T.

Xenobiotica. 2012 Dec;42(12):1187-96. doi: 10.3109/00498254.2012.700140. Epub 2012 Jul 27.

PMID:
22834478
18.

Insight into new potential targets for the treatment of overactive bladder and detrusor overactivity.

Cerruto MA, Asimakopoulos AD, Artibani W, Del Popolo G, La Martina M, Carone R, Finazzi-Agrò E.

Urol Int. 2012;89(1):1-8. doi: 10.1159/000339251. Epub 2012 Jun 27. Review.

PMID:
22738896
19.

Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.

Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C.

BJU Int. 2012 Jul;110(2 Pt 2):E132-42. doi: 10.1111/j.1464-410X.2012.11240.x.

20.

A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.

Ohlstein EH, von Keitz A, Michel MC.

Eur Urol. 2012 Nov;62(5):834-40. doi: 10.1016/j.eururo.2012.05.053. Epub 2012 Jun 5.

PMID:
22695239

Supplemental Content

Support Center